These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31366601)

  • 41. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
    Schappell DL; Alper JC; McDonald CJ
    Arch Dermatol; 1995 Mar; 131(3):307-13. PubMed ID: 7887660
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emergence of Photosensitivity with Decreased Treg Cells in a Patient with Mycosis Fungoides Treated with Anti-CC Chemokine Receptor 4 Antibody Mogamulizumab.
    Tatsuno K; Sano T; Fukuchi K; Kuriyama S; Aoshima M; Kasuya A; Ikeya S; Fujiyama T; Ito T; Tokura Y
    Acta Derm Venereol; 2016 Mar; 96(3):420-1. PubMed ID: 26463269
    [No Abstract]   [Full Text] [Related]  

  • 43. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
    Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
    J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.
    Child F; Ortiz-Romero PL; Alvarez R; Bagot M; Stadler R; Weichenthal M; Alves R; Quaglino P; Beylot-Barry M; Cowan R; Geskin LJ; Pérez-Ferriols A; Hellemans P; Elsayed Y; Phelps C; Forslund A; Kamida M; Zinzani PL
    Br J Dermatol; 2016 Jul; 175(1):80-8. PubMed ID: 26836950
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Progression of CD8-positive Sézary syndrome from mycosis fungoides following dupilumab treatment.
    Fujii K; Yoshizaki A; Matsuoka A; Baba N; Ohshima K; Kanekura T
    Eur J Dermatol; 2024 Jun; 34(3):294-296. PubMed ID: 39015963
    [No Abstract]   [Full Text] [Related]  

  • 46. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model.
    Wang Z; Ma J; Zhang H; Ramakrishna R; Mintzlaff D; Mathes DW; Pomfret EA; Lucia MS; Gao D; Haverkos BM; Wang Z
    FEBS Open Bio; 2023 Jul; 13(7):1309-1319. PubMed ID: 37157185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Unleashed monocytic engagement in Sézary syndrome during the combination of anti-CCR4 antibody with type I interferon.
    Jiang TT; Kruglov O; Akilov OE
    Blood Adv; 2024 May; 8(10):2384-2397. PubMed ID: 38489234
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.
    Fernández-Guarino M; Ortiz P; Gallardo F; Llamas-Velasco M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396877
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome.
    Querfeld C; Rosen ST; Guitart J; Duvic M; Kim YH; Dusza SW; Kuzel TM
    Blood; 2014 Feb; 123(8):1159-66. PubMed ID: 24335103
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome.
    Prince HM; Querfeld C
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):322-335. PubMed ID: 30213403
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of autoimmunity and long-term complete remission in patients with Sézary syndrome treated with mogamulizumab.
    Bonnet P; Battistella M; Roelens M; Ram-Wolff C; Herms F; Frumholtz L; Bouaziz JD; Brice P; Moins-Teisserenc H; Bagot M; de Masson A
    Br J Dermatol; 2019 Feb; 180(2):419-420. PubMed ID: 30328116
    [No Abstract]   [Full Text] [Related]  

  • 52. Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome.
    Avilés A; Nambo MJ; Neri N; Castañeda C; Cleto S; Gonzalez M; Huerta-Guzmán J
    Cancer Biother Radiopharm; 2007 Dec; 22(6):836-40. PubMed ID: 18158775
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
    Dugas-Breit S; Schulze HJ; Hallermann C
    J Dtsch Dermatol Ges; 2014 Jul; 12(7):561-9. PubMed ID: 24889480
    [TBL] [Abstract][Full Text] [Related]  

  • 54. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome.
    Lundin J; Kennedy B; Dearden C; Dyer MJ; Osterborg A
    Blood; 2005 May; 105(10):4148-9. PubMed ID: 15867423
    [No Abstract]   [Full Text] [Related]  

  • 55. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication.
    Durgin JS; Weiner DM; Wysocka M; Rook AH
    J Am Acad Dermatol; 2021 Mar; 84(3):587-595. PubMed ID: 33352267
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.
    Devata S; Wilcox RA
    Am J Clin Dermatol; 2016 Jun; 17(3):225-37. PubMed ID: 26923912
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.
    Reddy SA
    Crit Rev Oncol Hematol; 2016 Oct; 106():99-107. PubMed ID: 27637355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mogamulizumab combined with extracorporeal photopheresis for the treatment of refractory mycosis fungoides and Sézary syndrome. Report of seven cases.
    Rubio-Muniz CA; Sánchez-Velázquez A; Arroyo-Andrés J; Agud-de Dios M; Tarín-Vicente EJ; Falkenhain-López D; Ortiz-Romero PL
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e102-e105. PubMed ID: 37611255
    [No Abstract]   [Full Text] [Related]  

  • 59. Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity.
    Nevet MJ; Zuckerman T; Sahar D; Bergman R
    Am J Dermatopathol; 2015 Jan; 37(1):73-7. PubMed ID: 25548993
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome.
    Mori T; Shiratori S; Suzumiya J; Kurokawa M; Shindo M; Naoyuki U; Katsuto T; Miyamoto T; Morishige S; Hirokawa M; Fukuda T; Atsuta Y; Suzuki R
    Hematol Oncol; 2020 Aug; 38(3):266-271. PubMed ID: 32011008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.